BnR Summit 2026

Belt & Road Summit - Deal-Making 2026

9 – 15 Sept 2026 | Hong Kong, China (Hong Kong)

Register
Register
Register

ProjectUpdated on 18 August 2026

Paradigm-shifting healthtech solution dealing with the deadliest health condition worldwide

CEO at AiMorphous Healthtech

China (Hong Kong)

About

Thrombosis is the number 1 disease condition causing most death and debilitation. Most of the thrombotic events are avoidable if early detection and warning technology is available. Today’s healthcare system does not have such technology to predict the individualized risk with high accuracy and help manage the risk. With our novel tech, together with precise pharmaceutical intervention, future healthcare will experience better anti-thrombotic treatment with dramatic reduction in recurrent bleeding and thrombosis through breakthrough early blood biomarker and novel predictive AI modelling method, solving the decade-old technical difficulties in early detection and accurate individual risk prediction problem. Product range: reagent kit, software and hardware.

Project Location

  • China (Hong Kong)

Project Format

  • Private Project

Go Global Project

  • Yes

ESG (Environmental, Social, and Governance)

  • Yes

Project Stage

  • Investment / Financing Discussion

Main Project Sector

  • Technology

Manufacturing

biotech, medical technology

Technology

  • Bio-Tech
  • Health Technology
  • Medical Technology

Total Project Value

  • 25,000,001 to 50,000,000 USD

Investment Capital Required

  • 2,500,001 to 5,000,000 USD

Interested Format of Cooperation

  • Direct Equity Investment

Preferred Financing Model

  • Equity
  • Public / Alternative Financing
  • Open for negotiation

Type(s) of Last Financing Round of the project (if Applicable)

  • Convertible Loan

Main Service(s) Required

  • Financial Services
  • Professional Services

Organisation

AiMorphous Healthtech

China (Hong Kong)

Similar opportunities